FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCharles River Laboratories International, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CRL
Charles River Laboratories International, Inc. Stock AnalysisComprehensive stock analysis for Charles River Laboratories International, Inc. (CRL) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCRL
CRL
Charles River Laboratories International, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CRL
  1. Home
  2. Stocks
  3. Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

🇺🇸CRL•NYSE

Charles River Laboratories International, Inc.

🇺🇸CRL•NYSE
Market cap
$16.08B
Sentiment

Your view on CRL

Mkt Cap
$16.08B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Charles River Laboratories International, Inc.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
James C. Foster
Headquarters
251 Ballardvale Street, Wilmington, MA, US
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
James C. Foster
Headquarters
251 Ballardvale Street, Wilmington, MA, US
Description

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.

It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers.

This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services.

The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services.

The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products.

This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines.

The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Charles River Laboratories International, Inc. from FRC's valuation model, read against the market price. CRL last traded at $335.52, 328.7× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Charles River Laboratories International, Inc.. Starting points for Charles River Laboratories International, Inc.: P/E 328.7, EPS $0.84, beta 1.34 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Charles River Laboratories International, Inc.. Charles River Laboratories International, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Charles River Laboratories International, Inc.. Trailing twelve-month EPS for Charles River Laboratories International, Inc. stands at $0.84. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$313.67

average of 15 firms, last 12 months

 

$313.67

Low $219.00

Median $330.00

High $388.00

 

Analyst Ratings

Buy13 firms, last 12 months
  • Strong Buy0
  • Buy11
  • Hold2
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$3.32$2.82$11.47$12.93
Low estimate$3.19$2.49$11.23$12.65
High estimate$3.44$3.25$11.59$13.58
No. of analysts9699
Year-ago EPS$2.39$2.06-$2.911—
Growth+38.9%+36.9%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$970.24M$989.38M$3.95B$4.06B
Low estimate$957.92M$976.99M$3.91B$3.99B
High estimate$980.66M$1.01B$3.98B$4.15B
No. of analysts851010
Year-ago revenue$994.23M$995.83M$4.02B—
Growth-2.4%-0.6%-1.7%—
Recent analyst actions15 rating and price-target changes, latest Nov 11, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Pulse 2.0, Benzinga; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Charles River Laboratories International, Inc.. Charles River Laboratories International, Inc. has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CRL16 companies · 8 funds
Compare CRL with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • CERTCertara, Inc.Medical - Healthcare Information Services$1.7B
  • GNNSFGenscript Biotech CorporationBiotechnology$3.8B
  • HNGZYHangzhou Tigermed Consulting Co., Ltd.Biotechnology$6.2B
  • ICLRICON Public Limited CompanyMedical - Diagnostics & Research$14.3B
  • MEDPMedpace Holdings, Inc.Medical - Diagnostics & Research$18.1B

More Medical - Diagnostics & Research companies

  • MBGNFMany Bright Ideas Technologies Inc.OTC$101,821
  • MDXHMDxHealth S.A.NASDAQ$14M
  • MEDDMedical Imaging Corp.OTC$63,819
  • MEDVFMedivolve Inc.OTC$54,038
  • MRCHFH.U. Group Holdings, Inc.OTC$1.1B
  • MRPSMicrophonics, Inc.OTC
  • MTDMettler-Toledo International Inc.NYSE$34.4B
  • MVF.AXMonash IVF Group LimitedASX
  • MYGNMyriad Genetics, Inc.NASDAQ$534M
  • NDRAENDRA Life Sciences Inc.NASDAQ$7M
  • NEONeoGenomics, Inc.NASDAQ$2.0B

ETFs holding Charles River Laboratories International, Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.03%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.02%
  • VBVanguard Small-Cap ETF$76.9B in assets0.21%
  • RSPInvesco S&P 500 Equal Weight ETF$101.8B in assets0.24%
  • FMTMMarketDesk Focused U.S. Momentum ETF$268M in assets3.23%
  • PTHInvesco Dorsey Wright Healthcare Momentum ETF$293M in assets2.48%
  • QMOMAlpha Architect U.S. Quantitative Momentum ETF$400M in assets2.47%
  • BBHVanEck Biotech ETF$536M in assets1.66%

Largest holders first, then the funds most concentrated in CRL.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Charles River Laboratories International, Inc., and how their positions are changing. At a $16.08B market value, institutional positions materially move Charles River Laboratories International, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Charles River Laboratories International, Inc. executives and directors. Shares of Charles River Laboratories International, Inc. have traded between $91.86 and $203.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Charles River Laboratories International, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Charles River Laboratories International, Inc.. Coverage tracks Charles River Laboratories International, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Charles River Laboratories International, Inc.

CRL Analysis
Fair
Past5
Growth2
Health3
Profit1
Value1

News

Latest Market News